Fortress Biotech
FBIO
49 hedge funds and large institutions have $9.31M invested in Fortress Biotech in 2019 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 12 increasing their positions, 13 reducing their positions, and 11 closing their positions.
27% more capital inflows, than outflows
Capital inflows: $3.16M | Capital outflows: $2.5M
9% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 11
0.09% more ownership
Funds ownership: 9.47% → 9.56% (+0.09%)
0% more funds holding
Funds holding: 49 → 49 (0)
8% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Opus Point Partners Management
New York
|
+$595K |
| 2 |
Nantahala Capital Management
New Canaan,
Connecticut
|
+$528K |
| 3 |
6CM
683 Capital Management
New York
|
+$314K |
| 4 |
CPWM LLC
Seattle,
Washington
|
+$309K |
| 5 |
Renaissance Technologies
New York
|
+$251K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$557K |
| 2 |
Northern Trust
Chicago,
Illinois
|
-$504K |
| 3 |
Millennium Management
New York
|
-$494K |
| 4 |
Paloma Partners
Greenwich,
Connecticut
|
-$246K |
| 5 |
Jane Street
New York
|
-$197K |
FBIO Hedge Fund Activity: Q3 2019 in Review
49 of the 4,576 institutional investors tracked by Wall St. Rank reported a position in Fortress Biotech (FBIO) for Q3 2019, worth a combined $9.31M — down 0.66% from $9.37M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new FBIO positions and 11 closed out — a net gain of 1 holder — while 12 added to existing stakes and 13 trimmed.
The largest buyer was Opus Point Partners Management, adding an estimated $595K. The largest seller was Vanguard Group, cutting an estimated $557K.
- 49 institutional investors held Fortress Biotech (FBIO) as of Q3 2019, unchanged from Q2 2019.
- Funds reported $9.31M of Fortress Biotech stock for Q3 2019, down 0.66% quarter-over-quarter.
- 12 funds opened new Fortress Biotech positions in Q3 2019 and 11 closed out, a net change of +1 holder.
- The largest Fortress Biotech buyer in Q3 2019 was Opus Point Partners Management, an estimated $595K added.
- The largest Fortress Biotech seller in Q3 2019 was Vanguard Group, an estimated $557K sold.
Based on aggregated 13F filings for Q3 2019.